Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 9/20 | 0.59 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SHMT2 | P34897 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1590723 | 1.00 | P2RX7 (0.59) | P2RX7KCNQ2TRPV1KMT2ASHMT2 | |
| SCHEMBL1591542 | 1.00 | P2RX7 (0.59) | P2RX7KCNQ2TRPV1KMT2ASHMT2 | |
| SCHEMBL1590725 | 1.00 | P2RX7 (0.59) | P2RX7KCNQ2TRPV1KMT2ASHMT2 | |
| SCHEMBL1590628 | 1.00 | P2RX7 (0.59) | P2RX7KCNQ2TRPV1KMT2ASHMT2 | |
| SCHEMBL1591054 | 1.00 | P2RX7 (0.59) | P2RX7KCNQ2TRPV1KMT2ASHMT2 | |
| SCHEMBL12702855 | 0.92 | P2RX7 (0.50) | P2RX7KCNQ2TRPV1KMT2ASHMT2 | |
| SCHEMBL1589981 | 0.89 | P2RX7 (0.47) | P2RX7KCNQ2TRPV1KMT2ASHMT2 | |
| SCHEMBL1589980 | 0.89 | P2RX7 (0.47) | P2RX7KCNQ2TRPV1KMT2ASHMT2 | |
| SCHEMBL1590406 | 0.86 | P2RX7 (0.44) | P2RX7KCNQ2TRPV1KMT2A | |
| SCHEMBL1590418 | 0.86 | P2RX7 (0.44) | P2RX7KCNQ2TRPV1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110092476-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. | 2011-04-21 | — | — | US | claimed |
| US-7816371-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. (US) | 2010-10-19 | — | — | US | claimed |
| US-20070225324-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | SECOND GENOME, INC. | 2007-09-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225324-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | P2RX7, P2RX3, P2RX2 | P2RX7 1/4885KCNQ2 519/4885TRPV1 19/4885 |
| US-20110092476-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | P2RX7, P2RX3, P2RX2 | P2RX7 1/4885KCNQ2 519/4885TRPV1 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.